Regeneron Joins Major Drugmakers in Pricing Concessions Under Trump Agreements for New and Existing Medicines

Regeneron Pharmaceuticals has entered into a drug pricing agreement with the Trump administration, becoming the 17th major pharmaceutical company to adopt most-favored-nation pricing for its medicines in the United States.

The agreement, announced on April 23, 2026, includes a commitment to reduce the price of Regeneron’s cholesterol-lowering drug Praluent from $537 to $225 for patients purchasing directly through the federal government’s new drug-pricing portal, TrumpRx.gov.

As part of the deal, Regeneron will provide its newly approved gene therapy, Otarmeni, at no cost to eligible U.S. Patients following regulatory approval. The treatment, which addresses a rare genetic form of hearing loss, received expedited approval from the U.S. Food and Drug Administration on the same day as the pricing agreement was announced.

The Trump administration stated that the 17 pharmaceutical companies now participating in these pricing agreements represent 86% of the branded drug market in the United States. Officials said the initiative aims to align U.S. Drug prices with the lowest prices paid by other developed nations, a policy referred to as most-favored-nation pricing.

Under the terms of the agreement, Regeneron will also be exempt from certain tariffs for three years, including potential levies on pharmaceutical products that the administration has proposed as part of its broader trade policy.